Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 582 • 2017 ACR/ARHP Annual Meeting
Low Dose Computed Tomography Detects More Progression of Bone Formation in Comparison to Conventional Radiography in Patients with Ankylosing Spondylitis
Anoek de Koning¹, Freek de Bruin², Rosaline van den Berg³, Sofia Ramiro⁴, Xenofon Baraliakos⁵, Jürgen Braun⁵, Floris van Gaalen³, M. Reijnierse⁶ and Désirée van der Heijde⁷, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²LUMC, Leiden, Netherlands, ³Rheumatology, LUMC, Leiden, Netherlands, ⁴Rheumatology, Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, ⁵Rheumazentrum Ruhrgebiet, Herne, Germany, ⁶Department of Radiology, Leiden University Medical Center, Leiden, Netherlands, ⁷Leiden University Medical Center, Leiden, Netherlands
Background/Purpose : A newly developed scoring method for low dose CT (ldCT) of the whole spine, CT Syndesmophyte Score (CTSS), has shown good inter-reader reliability…
Abstract Number: 1527 • 2017 ACR/ARHP Annual Meeting
Do TNF Inhibitors Alter the Natural History of Ankylosing Spondylitis By Impacting the Incidence and Prevalence of Comorbidities and Extra-Articular Manifestations?
Atul A. Deodhar¹, Kevin Winthrop², Benjamin Chan², Sarah A. R. Siegel², Lisa Pisenti³, Jeffrey Stark³, Robert Y. Suruki⁴, Rhonda L. Bohn⁴, Huifeng Yun⁵, Lang Chen⁵ and Jeffrey R. Curtis⁵, ¹Division of Arthritis & Rheumatic Diseases OP09, Oregon Health & Science University, Portland, OR, ²Oregon Health & Science University, Portland, OR, ³UCB Pharma, Smyrna, GA, ⁴UCB Pharma, Raleigh, NC, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Treatment with TNF inhibitors (TNFi) has led to a reduction in signs and symptoms, and improvement in physical function and quality of life in…
Abstract Number: 1563 • 2017 ACR/ARHP Annual Meeting
Long-Term Effects of TNF-Alpha Inhibitors on Bone Mineral Density and the Incidence of Vertebral Fractures in Patients with Ankylosing Spondylitis
Kim Beek¹, Mignon van der Weijden¹, WF Lems², Christiaan van Denderen³, M. Nurmohamed⁴ and Irene van der Horst - Bruinsma⁵, ¹Rheumatology, Amsterdam Rheumatology immunology Centre/VUmc and Reade, Amsterdam, Netherlands, ²Amsterdam Rheumatology and immunology Center | VU University Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, ³Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁴Rheumatology, Amsterdam Rheumatology and immunology Center, Reade, Amsterdam, Netherlands, ⁵ARC, Amsterdam, Netherlands, Amsterdam, Netherlands
Background/Purpose: Ankylosing Spondylitis (AS) is not only characterized by pathological bone formation leading to ankylosis, but also by bone loss which may lead to vertebral…
Abstract Number: 2520 • 2017 ACR/ARHP Annual Meeting
Incidence of Extra-Articular Manifestations in Psa and As Patients Treated with Golimumab in Canadian Real-World
Michelle Teo¹, Derek Haaland², John Kelsall³, Isabelle Fortin⁴, Pauline Boulos⁵, Raman Rai⁶, Sanjay Dixit⁷, B Haraoui⁸, Dalton Sholter⁹, Eliofotisti Psaradellis¹⁰, Emmanouil Rampakakis¹⁰, Brendan Osborne¹¹, Francois Nantel¹¹ and Allen J Lehman¹², ¹Balfour Medical Clinic, Penticton, BC, Canada, ²Rheumatology, Clinical Immunology & Allergy, McMaster University, Barrie, ON, Canada, ³Rheumatology, University of British Columbia, Vancouver, BC, Canada, ⁴Centre de Rhumatologie De l’Est du Quebec, Rimouski, QC, Canada, ⁵Rheumatology, McMaster University, Hamilton, ON, Canada, ⁶Private Practice, Hamilton, ON, Canada, ⁷Rheumatology, McMaster University Hamilton, Burlington, ON, Canada, ⁸Institut de Recherche en Rhumatologie de Montréal (IRRM), Montreal, QC, Canada, ⁹Rheumatology Associates, Edmonton, AB, Canada, ¹⁰JSS Medical Research, Montreal, QC, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹²Janssen Inc., Toronto, ON, Canada
Background/Purpose: Spondyloarthropathies (SpA) encompass a heterogeneous group of chronic inflammatory diseases affecting axial and peripheral joints. Besides articular symptoms, patients also experience extra-articular manifestations (EAMs)…
Abstract Number: 585 • 2017 ACR/ARHP Annual Meeting
Frequencies of Ligament Ossification in Patients with Ankylosing Spondylitis According to Several Ligaments Around Spine By Whole Spine CT Scan
Ran Song¹, Ji-Young Choi², Yeon-Ah Lee², Seung-Jae Hong², Hyung-In Yang³ and Sang-Hoon Lee¹, ¹Rheumatology, Kyung Hee University Hospital at Gang dong, Seoul, Korea, Republic of (South), ²Rheumatology, Kyung Hee University Hospital, Seoul, Korea, Republic of (South), ³Kyung Hee University Hospital at Gang dong, Seoul, Korea, Republic of (South)
Background/Purpose: Ankylosing spondylitis is chronic inflammatory arthritis with ligament ossification in spine such as ant. longitudinal ligaments, post. longitudinal ligaments, or other several ligaments around…
Abstract Number: 1528 • 2017 ACR/ARHP Annual Meeting
Secukinumab Provides Rapid and Sustained Pain Relief in Ankylosing Spondylitis Patients with Normal or Elevated Baseline CRP Levels and Correlated with Improvement in Fatigue
Atul A. Deodhar¹, Philip G. Conaghan², Tore K Kvien³, Vibeke Strand⁴, Lawrence Rasouliyan⁵, Brian Porter⁶, Steffen Jugl⁷ and Kunal Gandhi⁶, ¹Oregon Health & Science University, Portland, OR, ²University of Leeds, Leeds, United Kingdom, ³Diakonhjemmet Hospital, Oslo, Norway, ⁴Stanford University School of Medicine, Palo Alto, CA, ⁵RTI Health Solutions, Barcelona, Spain, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁷Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab has demonstrated sustained efficacy in patients (pts) with active AS.1,2 We investigated improvement in pain and fatigue scores from baseline (BL) through Week…
Abstract Number: 1565 • 2017 ACR/ARHP Annual Meeting
Depression and Fatigue in Patients with Ankylosing Spondylitis
Ji Hui Shin¹, Sun Ju Ahn² and Tae-Hwan Kim³, ¹rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ²Medical Research Coordinator, Hanyang Univerity Hospital for Rheumatic Disease Research Center, Seoul, Korea, Republic of (South), ³Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South)
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease that leads to bony ankyloses. The disease occurs in early adulthood, a critical stage in life,…
Abstract Number: 2524 • 2017 ACR/ARHP Annual Meeting
Weight Change before and after Diagnosis in Patients with Psoriatic Arthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis
Alexis Ogdie¹, Michael D. George², Joel Gelfand³, Maureen Dubreuil⁴, Thorvardur Love⁵ and Joshua Baker⁶, ¹Medicine/Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA, ²Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania Health System , Philadelphia, PA, ⁴Clinical Epidemiology, Boston University School of Medicine, Boston, MA, ⁵Landspitali University Hospital, Reykjavik, Iceland, ⁶Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Rheumatoid arthritis (RA) has been associated with weight loss around the time of diagnosis; little is known about weight change around diagnosis in…
Abstract Number: 614 • 2017 ACR/ARHP Annual Meeting
Effect of Tofacitinib on Reducing Pain in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Alexis Ogdie¹, Kurt de Vlam², Iain B. McInnes³, Philip J Mease⁴, Philip Baer⁵, Tatjana Lukic⁶, Kenneth Kwok⁶, Cunshan Wang⁷, Ming-Ann Hsu⁷ and Anna Maniccia⁶, ¹Division of Rheumatology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²UZ Leuven, Leuven, Belgium, ³Glasgow Biomedical Research Centre, University of Glasgow, Glasgow, United Kingdom, ⁴Swedish Medical Center and University of Washington, Seattle, WA, ⁵Baer Weinberg MPC, Scarborough, ON, Canada, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA), which has also been evaluated in other inflammatory rheumatic diseases…
Abstract Number: 1529 • 2017 ACR/ARHP Annual Meeting
Secukinumab Demonstrates Consistent Safety over Long-Term Exposure (up to 3 years) in Patients with Active Ankylosing Spondylitis: Pooled Analysis of Three Phase 3 Trials
Atul A. Deodhar¹, Xenofon Baraliakos², Helena Marzo-Ortega³, Joachim Sieper⁴, Mats Andersson⁵, Brian Porter⁶ and Todd Fox⁵, ¹Oregon Health & Science University, Portland, OR, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ³NIHR LBRC, LTHT and LIRMM, UoL, Leeds, United Kingdom, ⁴Charité University Medicine Berlin, Berlin, Germany, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Secukinumab has demonstrated a consistent and reliable safety profile in three Phase 3 studies in ankylosing spondylitis (AS): MEASURE 1 (NCT01358175), MEASURE 2 (NCT01649375),…
Abstract Number: 1570 • 2017 ACR/ARHP Annual Meeting
Monocytes from Male Patients with Ankylosing Spondylitis Display Decreased Osteoclastogenesis and Decreased RANKL/OPG Ratio
Valéria F. Caparbo¹, Carla G.S. Saad¹, Julio C. B. Moraes², Artur J de Brum-Fernandes³ and Rosa M R Pereira⁴, ¹Rheumatology Division, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil, ²Rheumatology Division, Faculdade de Medicina da Universidade de Sao Paulo, São Paulo, Brazil, ³Rheumatology Division, Université de Sherbrooke, Rheumatology Division, Canada, Sherbrooke, QC, Canada, ⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil
Background/Purpose: Ankylosing Spondylitis (AS) is a chronic inflammatory disease characterized by new bone growth that leads to syndesmophyte formation and subsequent vertebral ankyloses, although AS…
Abstract Number: 2537 • 2017 ACR/ARHP Annual Meeting
Changes in Severity, Functional Status, and Wellbeing over Time Among Individuals with Ankylosing Spondylitis (AS) in Canada: Results from the RHUMADATA® Multicentre Registry
Shelagh Szabo¹, Sara Chehab², Louis Coupal³ and Denis Choquette⁴, ¹Broadstreet HEOR, Vancouver, BC, Canada, ²Novartis Pharmaceuticals Canada Inc., Montreal, QC, Canada, ³Institut de Recherche en Rhumatologie de Montréal (IRRM), Montréal, QC, Canada, ⁴University of Montreal Hospital Research Centre (CRCHUM), Notre Dame Hospital Montreal, Montreal, QC, Canada
Background/Purpose: While changes in disease severity, functional status, and patient wellbeing are commonly measured in AS trials, longitudinal data from real-world cohorts are fewer; particularly…
Abstract Number: 629 • 2017 ACR/ARHP Annual Meeting
Is Earlier Golimumab Treatment Initiation in Psa and As Patients Associated with Improved Outcomes?
Suneil Kapur¹, Proton Rahman², Michelle Teo³, Jodie Reis⁴, Rajwinder Dhillon⁵, Pauline Boulos⁶, Raman Rai⁷, Regan Arendse⁸, Julie Vaillancourt⁹, Emmanouil Rampakakis⁹, Allen J Lehman¹⁰, Francois Nantel¹¹ and Brendan Osborne¹¹, ¹University of Ottawa, 139 Greenbank Rd, Suite 203, ON, Canada, ²Rheumatology, St Claires Mercy Hospital, St Johns, NF, Canada, ³Balfour Medical Clinic, Penticton, BC, Canada, ⁴University of Saskatchewan, Saskatoon, SK, Canada, ⁵Private Practice, Niagara Falls, ON, Canada, ⁶Private Practice, Dundas, ON, Canada, ⁷Private Practice, Hamilton, ON, Canada, ⁸University of Saskatchewan, Saskatoon, ON, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Previous studies have suggested that treating patients earlier with biologics could improve disease outcomes. The aim of this analysis was to assess the impact…
Abstract Number: 1530 • 2017 ACR/ARHP Annual Meeting
Improvements in Sleep Problems and Pain in Patients with Active Ankylosing Spondylitis Treated with Intravenous Golimumab: 28-Week Results of the Phase III Trial
Atul A. Deodhar¹, John D. Reveille², Eric K. H. Chan³, Steven Peterson⁴, Nan Li⁴, Elizabeth C. Hsia⁵, Lilianne Kim⁴, Kim Hung Lo⁴, Diane D. Harrison⁴ and Chenglong Han⁶, ¹Division of Arthritis & Rheumatic Diseases OP09, Oregon Health & Science University, Portland, OR, ²University of Texas McGovern Medical School, Houston, TX, ³Janssen Global Services, LLC, Raritan, NJ, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, PA, ⁶Janssen Global Services, LLC, Malvern, PA
Background/Purpose: To investigate the effect of intravenously administered (IV) golimumab (GLM, 2 mg/kg), an anti-TNFα monoclonal antibody, on sleep problems, total back pain (TBP), and…
Abstract Number: 1572 • 2017 ACR/ARHP Annual Meeting
MHC Associations of Ankylosing Spondylitis in East Asians Are Driven By HLA-B Amino-Acid Position 97, Confirming Findings in European Descent Subjects
Geng Wang¹, Adrian Cortes², So-Young Bang³, Paul Leo⁴, Matthew Brown⁴, Tae-Hwan Kim⁵ and Huji Xu¹, ¹Department of Rheumatology and Immunology, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai, China, ²Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom, ³Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ⁴Translational Genomics Group, Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, Australia, ⁵Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South)
Background/Purpose: Whilst HLA-B27 is the MHC allele associated with AS, there is strong evidence indicating that other HLA-B alleles and MHC genes are involved in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.